Financial Results: Lipocine Inc. reported a net loss of $3.2 million for Q3 2025, with total revenues of $114,574, a significant decrease from $7.7 million in the same period in 2024. The company had $15.1 million in cash and equivalents as of September 30, 2025.
LPCN 1154 for Postpartum Depression: The Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression, is ongoing, with top-line data expected in Q2 2026. A safety update will follow a review by the Data Safety Monitoring Board in November 2025.
LPCN 2101 for Epilepsy: Lipocine is considering a Phase 2 study for LPCN 2101, a treatment for epilepsy, and has two abstracts accepted for presentation at the upcoming American Epilepsy Society meeting in December 2025.
LPCN 2401 for Obesity Management: The company is exploring a Phase 2 study for LPCN 2401, aimed at obesity management, and is also looking for potential partnerships for commercialization of its drug candidates, including LPCN 1154 and LPCN 2401.
Wall Street analysts forecast LPCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LPCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.380
Low
6.75
Averages
6.88
High
7.00
Current: 10.380
Low
6.75
Averages
6.88
High
7.00
H.C. Wainwright
NULL -> Buy
upgrade
$7 -> $15
2026-01-21
Reason
H.C. Wainwright
Price Target
$7 -> $15
AI Analysis
2026-01-21
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Lipocine to $15 from $7 and keeps a Buy rating on the shares. The firm says LPCN 1154 showed a favorable safety profile.
H.C. Wainwright
H.C. Wainwright
Buy -> Buy
downgrade
$8 -> $7
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $7
2025-11-13
downgrade
Buy -> Buy
Reason
H.C. Wainwright lowered the firm's price target on Lipocine to $7 from $8 and keeps a Buy rating on the shares following the Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LPCN
Unlock Now
H.C. Wainwright
Yi Chen
initiated
$8
2025-05-29
Reason
H.C. Wainwright
Yi Chen
Price Target
$8
2025-05-29
initiated
Reason
H.C. Wainwright analyst Yi Chen assumed coverage of Lipocine with a Buy rating and $8 price target. Lipocine's first commercialized product, Tlando, an oral treatment indicated for testosterone replacement therapy, was approved by the FDA in 2022 and its current lead pipeline candidate is LPCN 1154, which is a rapid onset, oral formulation of the neuroactive steroid brexanolone for the treatment of postpartum depression, the analyst tells investors. If successfully developed, LPCN 1154 could "bring significant value to the company," says the analyst, who notes that the firm's current valuation is primarily based on market prospects for LPCN 1154.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
